美国 · SEC FORM 4
Cartesian Therapeutics, Inc.
RNAC · Nasdaq · CIK 0001453687 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-04 · BARABE TIMOTHY C.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,855,626
- 上期报告
- 1,803,282
- 日均成交量
- 146,843
- 回补天数
- 12.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-04 | BARABE TIMOTHY C | 买入 (P) | Common Stock | 30,000 | USD 6.86 | USD 205,800 | SEC 申报 ↗ |
| 2025-04-11 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 42,750 | USD 10.77 | USD 460,418 | SEC 申报 ↗ |
| 2025-04-10 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 57,170 | USD 10.46 | USD 598,273 | SEC 申报 ↗ |
| 2025-04-09 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 49,155 | USD 9.43 | USD 463,640 | SEC 申报 ↗ |
| 2025-03-20 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 54,889 | USD 15.59 | USD 855,720 | SEC 申报 ↗ |
| 2025-03-19 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 20,234 | USD 14.97 | USD 302,903 | SEC 申报 ↗ |
| 2025-03-18 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 14,740 | USD 14.42 | USD 212,551 | SEC 申报 ↗ |
| 2025-01-14 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 4,022 | USD 18.00 | USD 72,396 | SEC 申报 ↗ |
| 2025-01-13 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 16,945 | USD 17.35 | USD 293,957 | SEC 申报 ↗ |
| 2024-12-23 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 5,181 | USD 19.00 | USD 98,439 | SEC 申报 ↗ |
| 2024-12-20 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 21,800 | USD 18.94 | USD 412,892 | SEC 申报 ↗ |
| 2024-12-19 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 25,208 | USD 18.00 | USD 453,674 | SEC 申报 ↗ |
| 2024-11-18 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 58,295 | USD 18.12 | USD 1,056,261 | SEC 申报 ↗ |
| 2024-11-15 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 277,246 | USD 17.09 | USD 4,738,134 | SEC 申报 ↗ |
| 2024-11-14 | SPRINGER TIMOTHY A | 买入 (P) | Common Stock | 96,399 | USD 16.37 | USD 1,578,049 | SEC 申报 ↗ |
Form 4 申报证据
23 transaction lines in the latest 365-day window; 314 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Kalayoglu Murat | 期权行权／转换 (M) | Common Stock | 758,001 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-02 | Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust | 期权行权／转换 (M) | Common Stock | 758,001 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | Singer Michael | 赠与 (G) | Common Stock | 6,555 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (23 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Kalayoglu Murat | 期权行权／转换 (M) | Common Stock | 758,001 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-02 | Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust | 期权行权／转换 (M) | Common Stock | 758,001 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-13 | Singer Michael | 赠与 (G) | Common Stock | 6,555 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | Miljkovic Milos | 卖出 (S) | Common Stock | 3,573 | USD 6.82 | USD 24,368 | SEC 申报 ↗ |
| 2026-01-06 | Davis Blaine | 卖出 (S) | Common Stock | 10,591 | USD 6.82 | USD 72,231 | SEC 申报 ↗ |
| 2026-01-06 | Brunn Carsten | 卖出 (S) | Common Stock | 23,766 | USD 6.82 | USD 162,084 | SEC 申报 ↗ |
| 2026-01-02 | ZENNER PATRICK J | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Singer Michael | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Seymour June Ann | 奖励／授予 (A) | Common Stock | 6,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | SPRINGER TIMOTHY A | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Miljkovic Milos | 奖励／授予 (A) | Common Stock | 27,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Malik Kemal | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Kalayoglu Murat | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | English Emily | 奖励／授予 (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | DeSilva Nishan M | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Davis Blaine | 奖励／授予 (A) | Common Stock | 37,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Brunn Carsten | 奖励／授予 (A) | Common Stock | 143,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | BARABE TIMOTHY C | 奖励／授予 (A) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-30 | English Emily | 期权行权／转换 (M) | Common Stock | 7,500 | USD 3.30 | USD 24,750 | SEC 申报 ↗ |
| 2025-12-16 | Bot Adrian Ion | 奖励／授予 (A) | Common Stock | 5,800 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-04 | BARABE TIMOTHY C | 买入 (P) | Common Stock | 30,000 | USD 6.86 | USD 205,800 | SEC 申报 ↗ |
| 2025-11-28 | English Emily | 期权行权／转换 (M) | Common Stock | 7,500 | USD 3.30 | USD 24,750 | SEC 申报 ↗ |
| 2025-11-18 | Singer Michael | 赠与 (G) | Common Stock | 20,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RNAC |
| CIK | 0001453687 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 314 transaction lines from 2020-01-16 to 2026-04-02 86 P purchase lines · 75 S sale lines · 153 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.